Ipsen goes global with Japanese approval for Somatuline
This article was originally published in Scrip
Executive Summary
Ipsen can now claim to a be global pharmaceutical company following the announcement by its partner Teijin that it has received manufacturing and marketing approval from Japan's Ministry of Health, Labour and Welfare for its somatostatin analogue Somatuline (lanreotide). Teijin is expected to launch the product in Japan in 1Q, 2013.